Circulating FGF21 Concentration, Fasting Plasma Glucose, and the Risk of Type 2 Diabetes: Results From the PREVEND Study
Authors' conclusion
Higher circulating FGF21 concentrations are independently associated with an increased risk of incident T2D in participants with a low fasting plasma glucose, making circulating FGF21 concentration a potential early biomarker for type 2 diabetes.
Study context
- Population
- PREVEND participants aged 52 ± 12 years, 50% male
- Participants
- 5,244 participants
- Exposure
- Higher vs lower circulating FGF21 concentration
- Outcome
- Incident T2D
- Follow-up
- 7.3 [6.1-7.7] years
Methodological detailspopulation-based (PREVEND), Cox proportional hazards models adjusted for potential confounders, Circulating FGF21 measured by Mesoscale U-PLEX immunoassay
- Population-based (PREVEND)
- Cox proportional hazards models adjusted for potential confounders
- Circulating FGF21 measured by Mesoscale U-PLEX immunoassay
Main finding
As reported in the abstract
Incident T2D per doubling of circulating FGF21
HR per doubling of FGF21 (fully adjusted), 95% CI 1.06-1.51; P = 0.008
1.26
Effect modification by FPG, consistent with stronger association at lower fasting glucose: interaction coefficient (P = 0.022)
−0.12
Observational data: associations, not effects.
Further findings
Circulating FGF21 concentration
- Median [IQR] FGF21, pg/mL
- 860 [525-1329]
Incident T2D · 7.3 [6.1-7.7] years of follow-up
- Participants who developed T2D
- 299 (5.7%)
Original publication
Circulating FGF21 Concentration, Fasting Plasma Glucose, and the Risk of Type 2 Diabetes: Results From the PREVEND Study. J Clin Endocrinol Metab. Published 19 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →